Height benefits after GnRHa treatment in girls aged over 6 years with central precocious puberty: a meta-analysis.

IF 2.9 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Pub Date : 2025-09-01 Epub Date: 2025-06-23 DOI:10.1007/s12020-025-04332-6

Ming Chen, Jie-Yu Sun, Xing Ji, Ming-Ming Ni

{"title":"Height benefits after GnRHa treatment in girls aged over 6 years with central precocious puberty: a meta-analysis.","authors":"Ming Chen, Jie-Yu Sun, Xing Ji, Ming-Ming Ni","doi":"10.1007/s12020-025-04332-6","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this meta-analysis was to evaluate the impact of gonadotropin-releasing hormone analog (GnRHa) treatment on height outcomes in girls aged over 6 years with central precocious puberty (CPP).Methods: A systematic search was performed across PubMed, Cochrane Library, Web of Science, MEDLINE, EMBASE, CNKI, and Wan Fang databases to identify eligible studies. The meta-analysis protocol was registered at PROSPERO, and the quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). A random-effects meta-analysis was used to synthesize data on height gain, final adult height (FAH), FAH standard deviation score (SDS), bone age, and the difference between FAH and target height (TH).Results: Fifteen studies including 1270 girls were identified. The results indicated that GnRHa therapy significantly improves height outcomes in girls with CPP aged over 6 years. By effectively delaying pubertal progression and bone age maturation, GnRHa treatment enables these girls to achieve a greater FAH and potentially surpass their TH. Meta-analysis showed that the GnRHa treatment group demonstrated significantly greater height gain (WMD = 2.52, 95% CI [1.66, 3.37]), FAH (WMD = (WMD = 3.18, 95% CI [1.49, 4.87]), and FAH minus TH (WMD = 0.61, 95% CI [0.42, 0.79]) compared to the control group. Additionally, bone age (WMD = -1.02, 95%CI [-1.99, -0.06]) was significantly lower than the control group. However, FAH SDS showed no significant difference between the groups (WMD = 0.09, 95%CI [-0.40, 0.58]).Conclusions: GnRHa treatment demonstrates substantial benefits in promoting height outcomes in girls over 6 years old with CPP. This meta-analysis contributes to the growing body of evidence supporting the efficacy of GnRHa in managing CPP and underscores the importance of early intervention to maximize height potential in affected individuals.","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"686-697"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-025-04332-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of this meta-analysis was to evaluate the impact of gonadotropin-releasing hormone analog (GnRHa) treatment on height outcomes in girls aged over 6 years with central precocious puberty (CPP).

Methods: A systematic search was performed across PubMed, Cochrane Library, Web of Science, MEDLINE, EMBASE, CNKI, and Wan Fang databases to identify eligible studies. The meta-analysis protocol was registered at PROSPERO, and the quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). A random-effects meta-analysis was used to synthesize data on height gain, final adult height (FAH), FAH standard deviation score (SDS), bone age, and the difference between FAH and target height (TH).

Results: Fifteen studies including 1270 girls were identified. The results indicated that GnRHa therapy significantly improves height outcomes in girls with CPP aged over 6 years. By effectively delaying pubertal progression and bone age maturation, GnRHa treatment enables these girls to achieve a greater FAH and potentially surpass their TH. Meta-analysis showed that the GnRHa treatment group demonstrated significantly greater height gain (WMD = 2.52, 95% CI [1.66, 3.37]), FAH (WMD = (WMD = 3.18, 95% CI [1.49, 4.87]), and FAH minus TH (WMD = 0.61, 95% CI [0.42, 0.79]) compared to the control group. Additionally, bone age (WMD = -1.02, 95%CI [-1.99, -0.06]) was significantly lower than the control group. However, FAH SDS showed no significant difference between the groups (WMD = 0.09, 95%CI [-0.40, 0.58]).

Conclusions: GnRHa treatment demonstrates substantial benefits in promoting height outcomes in girls over 6 years old with CPP. This meta-analysis contributes to the growing body of evidence supporting the efficacy of GnRHa in managing CPP and underscores the importance of early intervention to maximize height potential in affected individuals.

查看原文本刊更多论文

6岁以上中枢性性早熟女孩接受GnRHa治疗后身高改善：一项荟萃分析

目的：本荟萃分析的目的是评估促性腺激素释放激素类似物（GnRHa）治疗对6岁以上中枢性性早熟（CPP）女孩身高结局的影响。方法：系统检索PubMed、Cochrane Library、Web of Science、MEDLINE、EMBASE、CNKI和万方数据库，以确定符合条件的研究。在普洛斯彼罗注册了meta分析方案，采用纽卡斯尔-渥太华量表（NOS）评估纳入研究的质量。采用随机效应meta分析综合身高增加、最终成人身高（FAH）、FAH标准差评分（SDS）、骨龄、FAH与目标身高（TH）之差等数据。结果：共纳入15项研究，包括1270名女孩。结果表明，GnRHa治疗可显著改善6岁以上CPP女孩的身高结局。通过有效地延缓青春期发育和骨龄成熟，GnRHa治疗使这些女孩获得更大的FAH，并有可能超过TH。荟萃分析显示，与对照组相比，GnRHa治疗组的身高增加（WMD = 2.52, 95% CI[1.66, 3.37]）、FAH (WMD = (WMD = 3.18, 95% CI[1.49, 4.87])和FAH减TH （WMD = 0.61, 95% CI[0.42, 0.79]）显著高于对照组。骨龄（WMD = -1.02, 95%CI[-1.99, -0.06]）显著低于对照组。而FAH SDS组间差异无统计学意义（WMD = 0.09, 95%CI[-0.40, 0.58]）。结论：GnRHa治疗在提高6岁以上CPP女孩的身高结局方面显示出实质性的益处。这项荟萃分析为支持GnRHa治疗CPP的有效性提供了越来越多的证据，并强调了早期干预的重要性，以最大限度地提高受影响个体的身高潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

5.40%

发文量

295

审稿时长

1.5 months

期刊介绍： Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.